Incyte 52-week data from study evaluating povorcitinib in vitiligo patients

Incyte announced new 52-week data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib , an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. Results showed that treatment with oral povorcitinib was associated with substantial total body and facial repigmentation across all treatment groups at Week 52. These data were presented today in a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress 2023, held from October 11-14 in Berlin. “These 52-week results further support earlier data and reinforce the efficacy profile and potential of povorcitinib as an oral treatment for patients with extensive nonsegmental vitiligo,” said Kurt Brown, M.D., Vice President and Povorcitinib Global Program Head, Incyte. “At Incyte, we are deeply committed to addressing unmet needs in the vitiligo community and understanding how this disease can affect patients’ lives. Today’s data highlight exciting progress as we work to bring new potential treatment options to patients living with this immune-mediated skin condition.”